GlassScriptPhysician profile
Abigail Vecellio
NPI 1306503362
$2,903.59
in general payments reported to CMS, 2019-2025
11 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $643 · 2024: $935 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,290 · Travel and Lodging: $514 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.37 |
| Travel and Lodging | $514.22 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $828.86 | 2025 | General - Therapies |
| Gilead Sciences, INC. | $482.86 | 2024-2025 | Livdelzi, Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $449.47 | 2023-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $312.96 | 2023-2024 | Dupixent |
| Abbvie INC. | $287.82 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $150.00 | 2023 | Zeposia |
| Ardelyx, INC. | $137.92 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $124.74 | 2025 | Wegovy |
| Janssen Biotech, INC. | $99.00 | 2024 | Stelara |
| Madrigal Pharmaceuticals | $15.90 | 2024 | Resmetirom |
| Orphalan INC | $14.06 | 2024 | Cuvrior |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Vecellio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.